Story perspectives

UK Pharma Investment Plummets Amid Pricing Concerns

9/16/2025

46 10

Summary

Story summary

Major pharmaceutical companies have paused or canceled nearly £2bn in UK investments this year, affecting patient care.
US drugmaker MSD scrapped a £1bn London research center, while AstraZeneca halted a £200m expansion in Cambridge.
The UK’s drug pricing regime is viewed as a deterrent, with companies labeling the market a "contagion risk."
Foreign investment in the UK pharma sector has dropped nearly 60% since 2020.
The UK government faces challenges in balancing economic growth with sustainable drug pricing to attract pharmaceutical investments.

1 of 1

Story summary

Major pharmaceutical companies have paused or canceled nearly £2bn in UK investments this year, affecting patient care.
US drugmaker MSD scrapped a £1bn London research center, while AstraZeneca halted a £200m expansion in Cambridge.
The UK’s drug pricing regime is viewed as a deterrent, with companies labeling the market a "contagion risk."
Foreign investment in the UK pharma sector has dropped nearly 60% since 2020.
The UK government faces challenges in balancing economic growth with sustainable drug pricing to attract pharmaceutical investments.